iShares Biotechnology ETF
631 hedge funds and large institutions have $6.3B invested in iShares Biotechnology ETF in 2018 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 195 increasing their positions, 209 reducing their positions, and 46 closing their positions.
59% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 46
4% more funds holding
Funds holding: 609 → 631 (+22)
3% more capital invested
Capital invested by funds: $6.14B → $6.3B (+$162M)
7% less repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 209
3.29% less ownership
Funds ownership: 67.92% → 64.63% (-3.3%)
4% less funds holding in top 10
Funds holding in top 10: 23 → 22 (-1)
42% less call options, than puts
Call options by funds: $379M | Put options by funds: $654M
Top Buyers
| 1 |
DFO
Duquesne Family Office
New York
|
+$100M |
| 2 |
Two Sigma Investments
New York
|
+$41.2M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$26.6M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$24.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$23.1M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$217M |
| 2 |
Goldman Sachs
New York
|
-$175M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$101M |
| 4 |
N
Natixis
Paris,
France
|
-$58.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$53.9M |
IBB Hedge Fund Activity: Q3 2018 in Review
631 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2018, worth a combined $6.3B — up 2.6% from $6.14B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new IBB positions and 46 closed out — a net gain of 27 holders — while 195 added to existing stakes and 209 trimmed.
The largest buyer was Duquesne Family Office, adding an estimated $100M. The largest seller was Deutsche Bank, cutting an estimated $217M.
- 631 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2018, up from 609 in Q2 2018.
- Funds reported $6.3B of iShares Biotechnology ETF stock for Q3 2018, up 2.6% quarter-over-quarter.
- 73 funds opened new iShares Biotechnology ETF positions in Q3 2018 and 46 closed out, a net change of +27 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2018 was Duquesne Family Office, an estimated $100M added.
- The largest iShares Biotechnology ETF seller in Q3 2018 was Deutsche Bank, an estimated $217M sold.
Based on aggregated 13F filings for Q3 2018.